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Objective: To define a sub-set of functional goals and out-
comes relevant to children and families living with cerebral 
palsy following treatment with botulinum toxin type A using 
the International Classification of Functioning, Disability 
and Health for Children and Youth.
Methods: We identified treatment goals and treatment out-
comes from medical case records in 2102 assessments of 239 
children with cerebral palsy treated with botulinum toxin 
between 1994 and 2009. Goals were set through assessment 
and discussion by experienced clinicians, therapists, parents 
and children.
Results: There were 61 separate goals, mapping to 40 catego-
ries, falling mostly within Body Functions: b710 Mobility of 
joint functions (414 times); b770 Gait pattern functions (374 
times); b7351 Tone of muscles of one limb (117 times). A total 
of 93 separate treatment outcomes were identified, mapping 
to 51 categories. Two of the 3 most common outcomes corre-
spond to the 2 most common goals (gait pattern and mobility 
of joint functions). 
Conclusion: The International Classification of Functioning, 
Disability and Health for Children and Youth provides a use-
ful framework to categorize the reasons for using botulinum 
toxin in children and focuses the clinical consultation not 
only on impairments but also functional outcomes.
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INTRoduCTIoN
Cerebral palsy (CP) is the most common cause of severe dis-
ability in childhood (1) and the cause of more referrals to 
rehabilitation than any other diagnosis (2). A common clinical 
feature of CP is spasticity, which has a major impact on daily 
personal activities and can restrict participation in social and 
educational programmes. Botulinum toxin type A (BoNT-A) is 
an effective treatment for spasticity (3, 4), and has functional 
benefits when combined with other rehabilitation treatments (5). 
It reduces spasticity by blocking the release of the neurotransmit-
ter acetylcholine at the motor endplate (6). Although sprouting 
of the nerve to make new connections overcomes the effects 
of BoNT-A over a period of 4–6 months, there is a substantial 
window of opportunity for orthoses and therapy to address spe-
cific pre-determined goals of rehabilitation. BoNT-A has been 
demonstrated to show improvements in functional goals over and 
above those in a non-BoNT-A treatment group (5). Functional 
goals included catching a ball, maintaining a grasp on a scooter 
or cycle handle, activities involved with dressing, maintaining 
an eating utensil in the hand. In this paper, goals are defined 
as changes in impairment, activity limitation or participation 
restriction that are expected to be observed as a result of BoNT-
A treatment. Outcomes are defined as those changes that were 
observed and recorded following treatment. Given the potential 
complexity of the benefits of botulinum toxin treatment, a system 
to capture these effects and provide a structure to the clinical 
consultation process would assist clinical decision-making and 
provide a formal method of involving parents and children in 
discussion about treatment objectives. 
The International Classification of Functioning, Disability 
and Health for Children and Youth (ICF-CY) (7) provides the 
framework for facilitating accurate and effective communica-
tion, a common language for describing and classifying function 
and development in children and young people (8), both within 
the multidisciplinary team and for communication between 
regional health networks. The ICF-CY model describes func-
tioning in two components: Body Functions and Structures, 
and Activities and Participation. Within these components, the 
ICF has more than 1,400 categories (8), making it somewhat 
impractical for day-to-day use. In recognition of this, the World 
Health organization (WHo) has produced two generic ICF as-
sessment tools (9), but even commonly used generic tools that 
are validated and reliable are not always appropriate for specific 
conditions, e.g. CP (10). This is being addressed by the WHo 
with the formulation of condition-specific Core Sets to facilitate 
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use of the ICF in clinical practice for a dozen common diseases 
(11). However, rehabilitation centres still find limitations when 
using the ICF in clinical settings (12). The proposed solution 
is the use of “subsets”, which are more appropriate for each 
setting (12). As part of a service evaluation, we undertook a 
retrospective review (over the last 15 years) of the Botulinum 
Clinic case notes of 239 children in order to identify and review 
the goals and benefits of botulinum treatment of spasticity in 
children with CP. These goals and benefits were formulated by 
both parents and the medical team. These goals and benefits 
were then described in terms of the ICF-CY categories. The 
aim of the review was to build on existing methods to develop 
ICF-CY subsets. We propose that the resulting set of ICF-CY 
categories provides an appropriate subset to categorize goals and 
outcomes associated with treatment of spasticity using BoNT-A 
in children with CP. 
MeTHodS
In 1994, a botulinum toxin treatment regional service was set up in 
Yorkshire, uk. Children from hospitals throughout the north of eng-
land, an area which included up to 12 district and General Hospitals, 
attended the clinic through referral from local paediatricians, occu-
pational therapists or physiotherapists. The multidisciplinary service 
consisted of paediatric neurologist, rehabilitation medicine physician, 
paediatric physiotherapist, nurse and occupational therapist. The goals 
and outcomes of treatment were therefore the result of a consultation 
by an experienced multidisciplinary team of specialists in neurological 
(re)habilitation. Importantly, children with CP and their parents/carers 
were also involved both in the formulation of treatment goals and in 
reporting the outcomes of treatment, defined here as parent-reported 
changes in activity, participation, body structure or function, at each 
hospital clinic attendance. 
Children with a confirmed diagnosis of CP first treated with BoNT-A 
between 1994 and 2005 were included in the clinical service evaluation. 
Between 1994 and 2009, 239 children with CP referred for spasticity 
management received over 2000 clinical assessments, each undertaken 
with regard to botulinum toxin treatment. As part of a clinical service 
evaluation of the spasticity management clinic, a retrospective case 
note review was undertaken using a structured textual search. data was 
recorded using a predefined proforma, which captured classification of 
CP, age, botulinum toxin treatment details (dose, frequency, muscles 
treated), goals statement, patient- and clinician-reported benefits. Goals 
for treatment and treatment benefits (outcomes) were recorded in the 
medical records during consultations with parents and children. Goals 
were documented as aims of treatment, and were repeated in a letter to 
both children’s GP and referring consultant after the clinic appointment. 
outcomes were documented in the notes in follow-up clinics. All data 
was anonymised for coding and analysis. A standard method for coding 
the goals and benefits obtained from the medical records was used. The 
quality of the method was assessed in a pilot evaluation by the authors. 
Firstly, a sample of 10 medical records was examined and the goals and 
outcomes independently categorized by the authors into impairment (of 
Body Function and Structure), or function (Activity and Participation). 
These were mapped to the categories of the ICF-CY. Any differences were 
resolved through discussion. The pilot test highlighted no differences in 
the conceptual interpretation of the goals and outcomes into the ICF-CY 
categories. A full set of data from the rest of the medical notes was then 
extracted by a paediatric neurophysiotherapist. Frequency of goals and 
outcomes were presented using descriptive statistics. These were then 
further classified in terms of ICF-CY components and categories. A total 
of 239 children’s medical records were examined (Table I). 
All data extraction from the medical records was undertaken by a 
single experienced paediatric neurophysiotherapist. Goals and treat-
ment outcomes were collated and defined by the appropriate category of 
the ICF-CY (7). The process was straightforward, but if there was any 
uncertainty or ambiguity linking the ICF-CY to the goals or benefits, 
these were noted and discussed amongst the authors. For example, 
the goal (and benefit) “Improve(d) application of ankle-foot orthoses” 
might have been defined as d540: Dressing, rather than e1151: Assistive 
products and technology for personal use in daily living. This example 
of “uncertainty or ambiguity” highlights the process. There were no 
goals or benefits of treatment that could not directly be linked to the 
ICF-CY. An example of goals and outcomes, and their corresponding 
ICF-CY (7) codes, are given in Table II.
As an example of the process, Improve Hand Function was described 
as a goal of treatment in the medical notes on 19 occasions, and Improved 
Hand Function was noted as a benefit of treatment on 15 occasions. This 
maps to the second-level ICF-CY domain d440 Fine Hand use (d = Activi-
ties and Participation; Chapter 4 Mobility; d440 Fine Hand Use), defined 
by the ICF-CY as “Performing the coordinated actions of handling objects, 
picking up, manipulating and releasing them using one’s hand, fingers 
and thumb, such as required to lift coins off a table or turn a dial or knob. 
(Inclusions: picking up, grasping, manipulating and releasing; Exclusion: 
lifting and carrying objects) (7). Because the ICF-CY tree branches to 
deeper levels in different domains, dividing some categories into more 
component parts and defining these activities in greater detail, some goals 
and outcomes were defined at greater levels. The example above was at the 
second level, but the goal of treatment “Maintain gastrocnemius muscle 
Table I. Classification of children with cerebral palsy (CP) at initial 
botulinum toxin treatment episode
variables
Children, n
Total number of children 239
Male/Female 134/105
Age, years
Youngest age receiving botulinum treatment 1
oldest age receiving botulinum treatment 19
Age at first treatment, mean/median/mode 5 /5 /3 
Age at last treatment, mean/median/mode 8 /7 /7 
GMFCS, n
GMFCS I 33
GMFCS II 61
GMFCS III 39
GMFCS Iv 38
GMFCS v 10
Not GMFCS classified 58
CP classification, n 
Spastic diplegia 121
Hemiplegia 51
Quadriplegia 55
Monoplegia 1
Unclassified 11
Clinics and treatments
Total number of assessments 2,102
Total number of injections 1,849
lower limb injections/upper limb injections, n 1,752/97
Gastrocnemius, n 909
Hamstrings, n 331
Adductors, n 279
Biceps, n 29
Thenar eminence, n 25
Brachio-radialis, n 22
Treatment length, weeks, mean (min–max) 66 (1–536)
Injections received, n, mean (max) 8 (36)
Most clinics attended by child, n 13
Mean number of clinics attended 4
GMFCS: Gross Motor Function Classification System.
J Rehabil Med 43
1012 N. Preston et al.
length” navigates to the 4th level s75012 Muscles of the lower leg. Thus, 
the level to which the goals and outcomes are described is not defined by 
the study methodology but by the ICF-CY. 
ReSulTS
The sample appeared to be broadly representative of the general 
population, although there was a larger than normal proportion 
of children with only the lower limbs affected. The ratio of boys 
to girls was 1.28, which is comparable to the population ratio 
in europe of 1.33 (13). The proportion of diplegic children was 
49.8% compared with 13–25%, but proportions were similar in 
children with hemiplegia (21.3% compared with 21–40%) or 
involvement of all 4 limbs (23% compared with 20–43%) (2).
Sixty-one goals of treatment mapped to 40 categories of the 
ICF. For example, the goals “keep up with peers” and “Reduce 
falls” both mapped to d450 Walking (Activities and Participa-
tion). Table III shows the ICF codes and categories, and the 
number of times they were identified as goals, for all 239 
children. The most common ICF-classified goal was Mobility 
of Joint Functions, ICF Code b710 (414/2102 clinical assess-
ments). The most common outcome was Gait Pattern functions 
b770 (285/2102 assessments – the second most common goal). 
Ninety-three outcomes of treatment mapped to 51 categories, of 
which 34 were common categories with the goals. These com-
mon goals are shown in Table III, along with the number of times 
they were reported as benefits or outcomes of treatment. Table 
Iv lists the 17 remaining outcomes mapped to ICF categories. 
dISCuSSIoN
This paper uses the ICF-CY to define a comprehensive subset 
of functional goals and outcomes for the treatment of spasticity 
in children with CP using BoNT-A. No ICF Comprehensive 
Core Set currently exists for children with CP, and we do not 
propose that our method sets out to address this, but we be-
lieve that this framework of ICF-CY categories forms the first 
defined subset of the ICF-CY appropriate for use in a specific 
clinical setting, as proposed by Huber et al. (12). It serves as a 
guide for documenting changes at impairment and functional 
levels, and as a communication aid for referral and assessment. 
The approach for developing this subset from the ICF-CY 
differs from the construction of Core Sets commissioned by 
the WHo (11). The methods used to develop these Core Sets 
involved: a delphi exercise (expert view); a systematic review 
of randomized trials to find the views of researchers; empirical 
data collection using the ICF checklist to identify the common 
patient problems of chronic conditions (11); and the gathering 
of up to 36 international experts for training in the ICF before 
undertaking the development of the Core Sets under supervi-
sion and guidance of the ICF Research Group (14). The process 
took place at 3 conferences organized over 13 months, and 
produced Core Sets for 12 chronic conditions. 
Two types of Core Sets for each condition, Brief and Com-
prehensive, are described: the first for use in multidisciplinary 
assessment and the second for use in assessment of participants 
in a clinical study. 
The Comprehensive Core Set for a specific condition “is a list 
of ICF categories that includes as few categories as possible to 
be practical, but as many as necessary to be sufficiently com-
prehensive to describe in a comprehensive, multidisciplinary 
assessment the typical spectrum of problems in functioning of 
patients with a specific condition” (11). The use of the ICF is 
gaining recognition in rehabilitation centres across europe and 
beyond, and other methods to interpret goals and benefits using 
the ICF have been described recently (15–17). The approach we 
have used to develop a subset of the ICF-CY for children with 
CP focuses on goals for targeting spasticity using a specific 
intervention, and includes established outcomes of the inter-
vention. The benefit of this approach is use of directly reported 
patient/parent goals and outcomes of the clinical treatment in a 
specific clinical setting and patient group in clinical consulta-
tion. This approach may be more practical than those acknowl-
edged in terms of time and human resources, as this method 
involved a single research physiotherapist who collated and 
organized the data in approximately 100 days. We believe the 
specific intervention in a defined patient population provides a 
Table II. Example of goals and outcomes generated for one child: a girl aged 3 years 11 months at first injection clinic, treated over a period of 1 
year 8 months at a total of 3 separate clinics 
Goals of treatment outcomes of treatment
Goals ICF-CY domains and categories
Parent-reported 
outcomes of treatment
Clinically assessed 
outcomes of treatment ICF-CY domains and categories
Improve cosmetic 
appearance
b180 experience of self and time 
functions
Cosmetically improved b180 experience of self and 
time functions
Reduce spasticity b7351 Tone of muscles of one limb Improved passive range 
of movement 
b7100 Mobility of a single joint
Improve hand 
function
d440 Fine hand use Grips objects better d4401 Grasping
Prevent abnormal 
hand posture
b710 Mobility of joint functions
Improve application 
of orthoses
e1151 Assistive products and 
technology for personal use in daily 
living
Improved social 
confidence
b1266 Confidence
ICF-CY: International Classification of Functioning, Disability and Health for Children and Youth.
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focus for the reporting of goals and outcomes in consultation 
with clinical specialists. We propose that this, combined with 
the patient-reported goals and benefits, increases the specificity 
of the subset for use in this clinical setting. 
There are some limitations of using this approach. First of all, 
data was extracted from medical records by a single researcher. 
A second researcher would improve the validity of the subset, 
as linking the recorded goals and outcomes in medical notes to 
the ICF-CY categories is prone to the individual researcher’s 
interpretation. There is also the question of the single-site sam-
ple on which the data was drawn. There is the potential for bias 
in the recording of information within medical notes, as well as 
potential for incomplete record of the clinical consultation, as 
indicated perhaps by the 6 goals of treatment (Table II), which 
were not reported as an outcome of treatment. There is inher-
ent bias involved in any data extraction. A further potential 
for bias in this ICF-CY classifications subset is that, during 
the early years of the service, referrals and treatment interven-
tions focussed predominantly on lower limb spasticity: there 
were 100 botulinum treatments injections to the upper limb 
compared with 1749 injections to the lower limb. 
Children and their families express needs in terms of the goals 
to be achieved, and clinicians discuss and add to these goals fol-
lowing a clinical assessment. The medical records of 239 children 
Table III. International Classification of Functioning, Disability and Health (ICF) categories identified as treatment goals in 239 children with 
cerebral palsy
Code
2nd level 3rd level 4th level ICF category title Number of times as a goal Number of times as an outcome
ICF categories of the component Body Structures identified as treatment goals in 239 children with cerebral palsy treated with botulinum toxin
s75000 Bones of thigh 3 0
s75012 Muscles of lower leg 5 0
ICF categories of the component Body Functions identified as treatment goals in 239 children with cerebral palsy treated with botulinum
b180 experience of self and time functions 8 5
b280 Sensation of pain 1 2
b2801 Pain in body part 18 7
b455 exercise tolerance functions 8 23
b710 Mobility of joint functions 414 88
b7100 Mobility of a single joint 9 69
b7101 Mobility of several joints 82 44
b715 Stability of joint functions 5 0
b7350 Tone of isolated muscles and muscle groups 9 7
b7351 Tone of muscles of one limb 117 42
b7353 Tone of muscles of lower half of body 46 11
b750 Motor reflex functions 1 0
b755 Involuntary movement reaction functions 15 52
b760 Control of voluntary movement functions 15 11
b765 Involuntary movement functions 14 13
b770 Gait pattern functions 374 285
ICF categories of the component Activities and Participation identified as treatment goals in 239 children with cerebral palsy treated with 
botulinum
d340 Producing messages in formal sign language 3 1
d4104 Standing 109 113
d415 Maintaining a body position 34 25
d4153 Maintaining a sitting position 22 33
d440 Fine hand use 19 16
d4401 Grasping 1 3
d4452 Reaching 7 1
d450 Walking 56 69
d450-d469 Walking and moving 2 5
d4551 Climbing 1 10
d460 Moving around in different locations 15 34
d465 Moving around using equipment 85 51
d510 Washing oneself 15 13
d530 Toileting 15 8
d540 dressing 4 1
d5700 ensuring one’s physical comfort 20 0
d599 Self-care, unspecified 10 3
d630–d649 Household tasks 6 0
ICF categories of Environmental Factors identified as treatment goals in 239 children with cerebral palsy treated with botulinum
e310  Support and Relationships (Immediate family) 3 11
e580 Health services, systems and policies 7 34
e5800 Health services 10 1
e1151 Assistive products and technology for personal 
use in daily living
63 69
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with CP, first treated with BoNT-A over an 11-year period, were 
reviewed and the goals and treatment outcomes collated and 
indexed to categories of the ICF-CY. A total of 57 ICF-CY cat-
egories describe these goals and benefits of treatment, of which 
34 were common to goals and benefits. The sample is broadly 
representative of the general population in terms of distribution 
of limb involvement: only diplegic children are over-represented, 
and this is likely to be a result of the focus on treatment of spastic-
ity of the lower limb during the early years of the clinic.
Goals and benefits from the clinics are classified under a 
total of 57 ICF Domains. The service evaluation identified 17 
ICF-CY categories describing benefits of treatment that had 
never been defined as a goal of treatment, and stresses the 
importance of parents in reporting outcomes of treatment. For 
example: 3 children found it easier to ride their bicycles, and 
4 were able to ride for the first time (d4750 Driving human-
powered transportation); 2 children were able to participate 
more in school activities (d8201 Maintaining an educational 
programme); 5 children reported that it was easier to play 
games (d880 engagement in play). one might consider these 
to be rather ambitious goals of treatment, but they are clearly 
potential outcomes in the treatment of children with CP that 
should not be overlooked in the assessment of more able 
children. on the other hand, 6 ICF-CY categories describing 
goals of treatment were not identified as outcomes. This may 
indicate that the treatment was unsuccessful, or the goals were 
not appropriate, but may suggest that the medical notes are not 
always comprehensive. Given the retrospective nature of this 
study it was not possible to use ICF qualifiers or facilitators 
to evaluate changes in functional states, as their scales are not 
sensitive for such purposes (12).
The subset could further be divided up into motor ability 
using the Gross Motor Function Classification System (GM-
FCS), or alternatively, distribution of spasticity. Although the 
GMFCS was not used in any of the clinical notes it was pos-
sible to classify gross motor function using the GMFCS from 
information documented in the medical records in 75.7% of 
children (Table II). 
Few domains were present from the environment chapter; 
this may indicate that the broader aspects of the impact of 
mediators and moderators on the clinical benefit were not 
specifically recorded in the way defined by the ICF, which uses 
a graded system of whether the environmental factor acts as 
Table Iv. Additional International Classification of Functioning, Disability and Health (ICF) categories identified as Outcomes of Treatment in 239 
children with cerebral palsy
ICF component
ICF Code
ICF domain/category
Times 
reported2nd level 3rd level
Body functions b1266 Confidence 19
Body functions b4550 General physical endurance 1
Body functions b4552 Fatiguability 7
Body functions b7102 Mobility of joints generalized 3
Body functions b7303 Power of muscles in lower half of the body 2
Body functions b7800 Sensation of muscle stiffness 2
Activities & Participation d4103 Sitting 1
Activities & Participation d4208 Transferring oneself, other specified 1
Activities & Participation d435 Moving objects with lower extremities 2
Activities & Participation d4402 Manipulating 2
Activities & Participation d4408 Fine hand use, other specified 2
Activities & Participation d4552 Running 12
Activities & Participation d4554 Swimming 2
Activities & Participation d4750 driving human-powered transportation 7
Activities & Participation d8201 Maintaining educational programme 2
Activities & Participation d880 engagement in play 5
Activities & Participation d9201 Sports 14
A summary of an ICF-based conceptualizing of the potential clinical impact of botulinum toxin in children with cerebral palsy is given in Fig. 1. 
We have illustrated this using the most common International Classification of Functioning, Disability and Health for Children and Youth (ICF-CY) 
categories identified as goals and benefits combined.
 
 
Cerebral palsy
Personal Factors  
Not explored
Body Structure & Functions
(see Table III)
Gait pattern functions
Mobility of joint functions
Tone of muscles of one
Mobility of several joints
Activities & Participation 
(see Table III)
Standing
Moving around using equipment
Walking
Maintaining a body position
Maintaining a sitting position
Moving around in different locations
Fine hand use
Environmental Factors
(see Table III)
Assistive products and technology for personal use 
in daily living 
Health Services, systems and policies 
Fig. 1. International Classification of Functioning, Disability and Health 
(ICF) model conceptualizing botulinum toxin A treatment of children with 
cerebral palsy using the most common categories of goals and benefits 
of treatment in 239 children.
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a barrier or a facilitator. The ICF conceptual framework and 
the use of this ICF-CY subset would aid in improving clinical 
consultations and medical record-keeping. At follow-up ap-
pointments, many families expressed concern about the timing 
and adequacy of their child’s therapy programmes in relation to 
BoNT-A treatment: for example, the timing of orthotic appoint-
ments following treatment. We believe that using this subset of 
ICF-CY classifications as a standardized and consistent means 
of communication with local therapists will enhance the plan-
ning and delivery of therapy programmes. For example, the 
most common ICF-CY category from environmental Factors 
(e1151 Assistive products and technology for personal use in 
daily living) describes the improvement in benefits and toler-
ance of orthotic devices. 
Advantages of the proposed subset include improvement in 
goal-setting and communication within a clinical consultation, 
facilitation of coordination of therapy by different healthcare 
professionals, improved documentation of goals in medi-
cal records (18), and allowing the clinical consultation and 
treatment to focus on outcomes that are seen as important to 
children and their families. The use of a core data set based 
on ICF categories has the potential to encourage clinicians to 
seek goals for intervention in the activity and participation 
domains. This study shows that clinicians using rehabilita-
tion/habilitation interventions will often conceptualize their 
interventions in the function domain, which is not necessarily 
the most meaningful on a day-to-day basis for a child with CP, 
whereas goals in the activity/participation domains are those 
that are most allied to developing independence and lead to 
consideration of environmental/person factors. A further pos-
sible use of this subset is to aid the construction of a Patient 
Reported outcome Measure (PRoM) (19, 20) for use within a 
clinical setting but also in the context of clinical trials.
In conclusion, this paper demonstrates that the goals and 
outcomes of treatment using BoNT-A in children with CP are 
readily described using the ICF-CY. We recommend the use 
of these categories both for improved communication between 
healthcare professionals and for formal clinical documentation. 
An important factor in the development of this ICF-CY subset 
is the inclusion of outcomes reported by parents following 
treatment; these illustrate that clinicians should also target 
Activity and Participation domains to establish goals that are 
more significant for the family. This approach can complement 
the existing approach of ICF-Core Set development by using 
patient- and clinician-generated information arising from “real 
life” clinical consultations. 
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